NCT01361191已完成2 期
Early Treatment Stratification Based on PET Scan Response to R-MEGACHOP Followed by R-MEGACHOP or R-IFE Plus Peripheral Autologous Stem Cell Transplant (PBSCT) in Patients With Poor Prognosis DLBCL
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea38 个研究点 分布在 1 个国家目标入组 71 人开始时间: 2007年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 71
- 试验地点
- 38
- 主要终点
- Event free survival at 3y in pat with DLBCL with a-IPI>1 or a-IPI=1 and ß2 µglobulin>=3mg/dl in pat PET+ after 3cycles of R-MegaCHOP and early rescue with R-IFE+TAPH or in pat PET- after 3cycles R-MegaCHOP followed by 3cycles of R-MegaCHOP without TAPH
研究概览
简要总结
The aim of the study is to evaluate the event free survival at three years in patients with diffuse large B-cell lymphoma with poor prognostic factors receiving R-MegaCHOP as induction therapy. Patients with positive PET after three cycles of R-MegaCHOP receive early salvage treatment with R-IFE and autologous stem cell transplantation. Patients with negative PET after three cycles of R-MegaCHOP are treated with three additional cycles of R-MegaCHOP without transplant.
详细描述
In addition to the above:
- To evaluate the overall survival after three years.
- To determine the rate of global responses and complete remissions, uncertain and partial.
- To determine the duration of the complete response after the treatment termination.
- To carry out an exploratory follow up of the event free survival and the overall survival at 5 years.
- To evaluate the treatment toxicity according CTC criteria (version 3.0) of the National Cancer Institute (NCI).
- To asses the role of PET in the disease stage and response evaluation compared to CAT.
- To identify the predictable response factors after 6 cycles of treatment with R-MegaCHOP administrated every 21 days; or 3 cycles of R-MegaCHOP, followed by IFE+TAPH in patients with DLBCL of severe prognosis.
- To evaluate the therapeutic fulfillment of the R-MegaCHOP and R+IFE cycles of treatment and/or R-IFE in reference with delays with the cycles administration and reductions of the chemotherapy dose (planned dose administrated in the planned term).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •follicular lymphoma grade III diagnosed patients, diffuse large B-cell lymphoma, histologically confirmed with CD20+
- •aged between 18 and 65 years. Patients aged from 65 to 70 years can be included according to the investigator's criteria regarding the patients' global health status and the absence of excluding comorbidity.
- •IPI adjusted to the age over 1 or a-IPI and beta2-microglobulin equal or higher than 3 mg/dl
- •Punctuation in the ECOG grade from 0 to 4
- •Life expectancy over 12 weeks
- •Written informed consent form
- •New diagnosed patient without any previous treatment
排除标准
- •Existence of severe cardiac, pulmonary, neurologic, psychiatric and metabolic diseases not caused by the lymphoma.
- •uncontrolled high blood pressure (diastolic pressure in rest > 115 mmHg)
- •Altered hepatic function (bilirubin or AST/ALT superior or equal at 2 times the superior limit of normality) or renal (creatinine equal or superior at 1.5 times the superior limit of normality) not caused by the lymphoma.
- •other malignant neoplasias along the past 5 years, except skin tumors, excluded melanoma or carcinoma in situ of cervix
- •patients positive for HIV
- •patients with transformed follicular lymphoma
- •pregnant women or in nursing; women of childbearing age who do not use an adequate contraceptive method before being included in the study
- •ventricular ejection fraction inferior to 50%
- •patients with severe psychiatric diseases which can interfere with their ability for understanding the study (including alcoholism or drug addiction)
结局指标
主要结局
Event free survival at 3y in pat with DLBCL with a-IPI>1 or a-IPI=1 and ß2 µglobulin>=3mg/dl in pat PET+ after 3cycles of R-MegaCHOP and early rescue with R-IFE+TAPH or in pat PET- after 3cycles R-MegaCHOP followed by 3cycles of R-MegaCHOP without TAPH
时间窗: 5 years follow-up
次要结局
- To evaluate the overall survival after three years. Further secondary outcomes as described in study summary.(5 years follow-up)
研究者
研究点 (38)
Loading locations...
相似试验
终止
3 期
Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate CancerStage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8Stage II Prostate Cancer AJCC v8Stage IIA Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8NCT04457245Jonsson Comprehensive Cancer Center54
撤回
1 期
A Study of LY2181308 in Patients With Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT00415155Eli Lilly and Company60
已完成
不适用
EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma PatientsAdenocarcinoma of the ProstateNCT01402154Centre Hospitalier Universitaire de Nīmes361
已完成
3 期
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)Chronic Lymphocytic Leukemia (CLL)NCT01580228Merck Sharp & Dohme LLC44
已完成
3 期
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C MutationColorectal Cancer (CRC)NCT05198934Amgen160